Ghent University Academic Bibliography

Advanced

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A Osmanov, XiaoNan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner UGent, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, et al. (2011) LANCET ONCOLOGY. 12(8). p.773-784
abstract
Background : Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting. Methods : In this multicentre phase 3 trial, rituximab-naive or rituximab-sensitive patients aged 18 years or older with relapsed grade 1 or 2 follicular lymphoma were randomly assigned (1: 1) to receive five 35-day cycles consisting of intravenous infusions of rituximab 375 mg/m(2) on days 1, 8, 15, and 22 of cycle 1, and on day 1 of cycles 2-5, either alone or with bortezomib 1 . 6 mg/m(2), administered by intravenous injection on days 1, 8, 15, and 22 of all cycles. Randomisation was stratified by FLIPI score, previous use of rituximab, time since last therapy, and region. Treatment assignment was based on a computer-generated randomisation schedule prepared by the sponsor. Patients and treating physicians were not masked to treatment allocation. The primary endpoint was progression-free survival analysed by intention to treat. This trial has been completed and is registered with ClinicalTrials.gov, number NCT00312845. Findings : Between April 10, 2006, and Aug 12, 2008, 676 patients were randomised to receive rituximab (n=340) or bortezomib plus rituximab (n=336). After a median follow-up of 33 . 9 months (IQR 26 . 4-39 . 7), median progression-free survival was 11 . 0 months (95% CI 9 . 1-12 . 0) in the rituximab group and 12 . 8 months (11 . 5-15 . 0) in the bortezomib plus rituximab group (hazard ratio 0 . 82, 95% CI 0 . 68-0 . 99; p=0 . 039). The magnitude of clinical benefit was not as large as the anticipated prespecified improvement of 33% in progression-free survival. Patients in both groups received a median of five treatment cycles (range 1-5); 245 of 339 (72%) and 237 of 334 (71%) patients in the rituximab and bortezomib plus rituximab groups, respectively, completed five cycles. Of patients who did not complete five cycles, most discontinued early because of disease progression (77 [23%] patients in the rituximab group, and 56 [17%] patients in the bortezomib plus rituximab group). Rates of adverse events of grade 3 or higher (70 [21%] of 339 rituximab-treated patients vs 152 [46%] of 334 bortezomib plus rituximab treated patients), and serious adverse events (37 [11%] patients vs 59 [18%] patients) were lower in the rituximab group than in the combination group. The most common adverse events of grade 3 or higher were neutropenia (15 [4%] patients in the rituximab group and 37 [11%] patients in the bortezomib plus rituximab group), infection (15 [4%] patients and 36 [11%] patients, respectively), diarrhoea (no patients and 25 [7%] patients, respectively), herpes zoster (one [<1%] patient and 12 [4%] patients, respectively), nausea or vomiting (two [<1%] patients and 10 [3%] patients, respectively) and thrombocytopenia (two [<1%] patients and 10 [3%] patients, respectively). No individual serious adverse event was reported by more than three patients in the rituximab group; in the bortezomib plus rituximab group, only pneumonia (seven patients [2%]) and pyrexia (six patients [2%]) were reported in more than five patients. In the bortezomib plus rituximab group 57 (17%) of 334 patients had peripheral neuropathy (including sensory, motor, and sensorimotor neuropathy), including nine (3%) with grade 3 or higher, compared with three (1%) of 339 patients in the rituximab group (no events of grade >= 3). No patients in the rituximab group but three (1%) patients in the bortezomib plus rituximab group died of adverse events considered at least possibly related to treatment. Interpretation : Although a regimen of bortezomib plus rituximab is feasible, the improvement in progression-free survival provided by this regimen versus rituximab alone was not as great as expected. The regimen might represent a useful addition to the armamentarium, particularly for some subgroups of patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PREDNISONE, VINCRISTINE, COMBINATION, CYCLOPHOSPHAMIDE, MULTIPLE-MYELOMA, MAINTENANCE THERAPY, LOW-GRADE, INDOLENT LYMPHOMA, MANTLE CELL LYMPHOMAS, NON-HODGKINS-LYMPHOMA
journal title
LANCET ONCOLOGY
Lancet Oncol.
volume
12
issue
8
pages
773 - 784
Web of Science type
Article
Web of Science id
000293272100028
JCR category
ONCOLOGY
JCR impact factor
22.589 (2011)
JCR rank
4/190 (2011)
JCR quartile
1 (2011)
ISSN
1470-2045
DOI
10.1016/S1470-2045(11)70150-4
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2001994
handle
http://hdl.handle.net/1854/LU-2001994
date created
2012-01-24 15:43:59
date last changed
2016-12-19 15:42:53
@article{2001994,
  abstract     = {Background : Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well tolerated in a randomised phase 2 study in patients with follicular and marginal zone lymphoma. We compared the efficacy and safety of rituximab alone or combined with bortezomib in patients with relapsed or refractory follicular lymphoma in a phase 3 setting. 
Methods : In this multicentre phase 3 trial, rituximab-naive or rituximab-sensitive patients aged 18 years or older with relapsed grade 1 or 2 follicular lymphoma were randomly assigned (1: 1) to receive five 35-day cycles consisting of intravenous infusions of rituximab 375 mg/m(2) on days 1, 8, 15, and 22 of cycle 1, and on day 1 of cycles 2-5, either alone or with bortezomib 1 . 6 mg/m(2), administered by intravenous injection on days 1, 8, 15, and 22 of all cycles. Randomisation was stratified by FLIPI score, previous use of rituximab, time since last therapy, and region. Treatment assignment was based on a computer-generated randomisation schedule prepared by the sponsor. Patients and treating physicians were not masked to treatment allocation. The primary endpoint was progression-free survival analysed by intention to treat. This trial has been completed and is registered with ClinicalTrials.gov, number NCT00312845. 
Findings : Between April 10, 2006, and Aug 12, 2008, 676 patients were randomised to receive rituximab (n=340) or bortezomib plus rituximab (n=336). After a median follow-up of 33 . 9 months (IQR 26 . 4-39 . 7), median progression-free survival was 11 . 0 months (95\% CI 9 . 1-12 . 0) in the rituximab group and 12 . 8 months (11 . 5-15 . 0) in the bortezomib plus rituximab group (hazard ratio 0 . 82, 95\% CI 0 . 68-0 . 99; p=0 . 039). The magnitude of clinical benefit was not as large as the anticipated prespecified improvement of 33\% in progression-free survival. Patients in both groups received a median of five treatment cycles (range 1-5); 245 of 339 (72\%) and 237 of 334 (71\%) patients in the rituximab and bortezomib plus rituximab groups, respectively, completed five cycles. Of patients who did not complete five cycles, most discontinued early because of disease progression (77 [23\%] patients in the rituximab group, and 56 [17\%] patients in the bortezomib plus rituximab group). Rates of adverse events of grade 3 or higher (70 [21\%] of 339 rituximab-treated patients vs 152 [46\%] of 334 bortezomib plus rituximab treated patients), and serious adverse events (37 [11\%] patients vs 59 [18\%] patients) were lower in the rituximab group than in the combination group. The most common adverse events of grade 3 or higher were neutropenia (15 [4\%] patients in the rituximab group and 37 [11\%] patients in the bortezomib plus rituximab group), infection (15 [4\%] patients and 36 [11\%] patients, respectively), diarrhoea (no patients and 25 [7\%] patients, respectively), herpes zoster (one [{\textlangle}1\%] patient and 12 [4\%] patients, respectively), nausea or vomiting (two [{\textlangle}1\%] patients and 10 [3\%] patients, respectively) and thrombocytopenia (two [{\textlangle}1\%] patients and 10 [3\%] patients, respectively). No individual serious adverse event was reported by more than three patients in the rituximab group; in the bortezomib plus rituximab group, only pneumonia (seven patients [2\%]) and pyrexia (six patients [2\%]) were reported in more than five patients. In the bortezomib plus rituximab group 57 (17\%) of 334 patients had peripheral neuropathy (including sensory, motor, and sensorimotor neuropathy), including nine (3\%) with grade 3 or higher, compared with three (1\%) of 339 patients in the rituximab group (no events of grade {\textrangle}= 3). No patients in the rituximab group but three (1\%) patients in the bortezomib plus rituximab group died of adverse events considered at least possibly related to treatment. 
Interpretation : Although a regimen of bortezomib plus rituximab is feasible, the improvement in progression-free survival provided by this regimen versus rituximab alone was not as great as expected. The regimen might represent a useful addition to the armamentarium, particularly for some subgroups of patients.},
  author       = {Coiffier, Bertrand and Osmanov, Evgenii A and Hong, XiaoNan and Scheliga, Adriana and Mayer, Jiri and Offner, Fritz and Rule, Simon and Teixeira, Adriana and Walewski, Jan and de Vos, Sven and Crump, Michael and Shpilberg, Ofer and Esseltine, Dixie-Lee and Zhu, Eugene and Enny, Christopher and Theocharous, Panteli and van de Velde, Helgi and Elsayed, Yusri A and Zinzani, Pier Luigi},
  issn         = {1470-2045},
  journal      = {LANCET ONCOLOGY},
  keyword      = {PREDNISONE,VINCRISTINE,COMBINATION,CYCLOPHOSPHAMIDE,MULTIPLE-MYELOMA,MAINTENANCE THERAPY,LOW-GRADE,INDOLENT LYMPHOMA,MANTLE CELL LYMPHOMAS,NON-HODGKINS-LYMPHOMA},
  language     = {eng},
  number       = {8},
  pages        = {773--784},
  title        = {Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial},
  url          = {http://dx.doi.org/10.1016/S1470-2045(11)70150-4},
  volume       = {12},
  year         = {2011},
}

Chicago
Coiffier, Bertrand, Evgenii A Osmanov, XiaoNan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, et al. 2011. “Bortezomib Plus Rituximab Versus Rituximab Alone in Patients with Relapsed, Rituximab-naive or Rituximab-sensitive, Follicular Lymphoma: a Randomised Phase 3 Trial.” Lancet Oncology 12 (8): 773–784.
APA
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., et al. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. LANCET ONCOLOGY, 12(8), 773–784.
Vancouver
1.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. LANCET ONCOLOGY. 2011;12(8):773–84.
MLA
Coiffier, Bertrand, Evgenii A Osmanov, XiaoNan Hong, et al. “Bortezomib Plus Rituximab Versus Rituximab Alone in Patients with Relapsed, Rituximab-naive or Rituximab-sensitive, Follicular Lymphoma: a Randomised Phase 3 Trial.” LANCET ONCOLOGY 12.8 (2011): 773–784. Print.